SubHero Banner

Lynparza® (olaparib) – New indication

December 19, 2018 - AstraZeneca and Merck announced the FDA approval of Lynparza (olaparib) tablets for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.

Download PDF